Mass General Brigham Ventures is an early-stage venture capital firm founded in 2008 to advance new life science technologies emerging from Mass General Brigham’s vast research network. Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide.
External link for Mass General Brigham Ventures
215 First Street
Cambridge, Massachusetts 02460, US
Congrats to MGBV portfolio company, Nocion Therapeutics, Inc., on expansion of their SAB and leadership team in preparation for their ASPIRE (Ph 2b) clinical trial for chronic cough.
We are delighted to welcome Catherine Bonuccelli and Joan Shaw to Nocion. Read the full press release here: https://lnkd.in/er6bZCHW
Congratulations to the QurAlis team on their new partnership with Eli Lilly and Company! We’re excited to see how Lilly and QurAlis move QRL-204 and UNC13A forward.
QurAlis is excited to announce that we have entered into an exclusive license agreement with Eli Lilly and Company under which QurAlis is granting Lilly global rights to develop and commercialize QRL-204, a potentially best-in-class splice-switching #ASO that restores #UNC13A function in #ALS, #FTD, and other #neurodegenerativediseases. #precisionmedicine Read more in our press release https://bit.ly/3R6QMT5
Our portfolio company, Tuesday Health, emerges from stealth with the attached press release. It is a model for how MGB Ventures works through private partnership commercialization to most effectively extend the impact of MGB innovation to improve healthcare for patients everywhere.
We're thrilled to announce the launch of our groundbreaking supportive care solution, backed by a $60 million investment from Valtruis, The Blue Venture Fund, Mass General Brigham Ventures, and CareSource. This initiative is set to transform the landscape of care for seriously ill patients and caregivers by providing earlier, more personalized support. As our CEO Jim Wieland puts it, "We're dedicated to providing support and care in the right setting, at the right time." A big thank you to our incredible partners and everyone involved in making this vision a reality. Together, we're making a significant impact on patient care and quality of life. Read more about this exciting development in our press release: https://hubs.la/Q02y0HjS0 #HealthcareInnovation #SupportiveCare #TuesdayHealth #PatientCare #HealthcareTransformation
Mass General Brigham Ventures reposted this
Boston life science founders, join us next week (Wednesday, May 22nd) for our first LIVE Investor Connect! Watch companies pitch, listen to feedback, interact with investors and socialize over drinks and appetizers. Guest investors: Katie Segien from Hercules Capital Sergine Brutus Sweeney, PhD, from Mass General Brigham Ventures David Prim, PhD from Broadview Ventures Learn more and sign up here ===> https://lnkd.in/gMR2jfmV In partnership with SciShield & Prendio See you in Boston! #lifesciencefunding #biotech #innovation #pitch #community
Affinia Therapeutics Presents Preclinical Data for Genetic Cardiomyopathy and Sporadic ALS Programs with Novel Cardiotropic and BBB-Penetrant AAV Capsids at the American Society of Gene & Cell Therapy 2024 Annual Meeting (prnewswire.com)
Mass General Brigham Ventures reposted this
We are excited to announce that our program is available to children, teens and young adults (ages 7-22) in Rhode Island and we are in-network with United and Harvard Pilgrim and, as of May 1st, also Blue Cross Blue Shield of Rhode Island. Apply now https://zurl.co/SmHN #rhodeisland #mentalhealthawarenessmonth #anxiety #ocd #nowavailable
Mass General Brigham Ventures reposted this
Translating Mediar’s science to the clinic is underway! Today we announce several pivotal milestones envisioned since our launch just over one year ago that further advance our first-in-class #fibrosis portfolio. As we accelerate meaningful progress, we remain passionately powered by our science for patient impact. Learn more: https://lnkd.in/ens3Him9 #biotech
Mass General Brigham Ventures reposted this
Slice of Healthcare's Take on our news yesterday: "The acquisition of Kinto by Rippl is not just a merger of companies but a fusion of compassionate, innovative visions aiming to disrupt traditional dementia care paradigms. By harnessing AI’s potential, Rippl is set to enhance the quality and accessibility of care, bringing hope and improved support to millions affected by dementia. This strategic move could very well set the benchmark for future care models in the healthcare industry, combining the efficiency of technology with the sensitivity of human touch." https://lnkd.in/gAhSnMG2